Lantern Pharma Inc. (LTRN) Discusses LP-184 Phase 1a Clinical Results and Implications for DNA Damage Repair-Deficient Tumors Transcript
Panna SharmaPresident, CEO & Director Okay. Thank you, everyone, for joining us today for our LP-184 clinical trial results webinar....
